– UK, Alderley Park – Redx Pharma (LON: REDX), the drug discovery and development company focused on oncology and fibrosis, today announced the appointment of Natalie Berner to its Board as a Non-Executive Director with effect from 19 May 2021.
“We are delighted to welcome Natalie onto the Redx Board to represent Redmile, one of the Company’s key investors who have been instrumental in helping us to raise the funds to successfully execute on our business plans. The Board and I look forward to working with Natalie to ensure that we continue to grow Redx into a successful biotech company focused on the treatment of cancer and fibrotic disease.” said Board Chairman, Iain Ross.
Natalie brings extensive experience in the healthcare sector to the Board and will represent RM Special Holdings 3 LLP, an affiliate of Redmile Group, LLC, a San Francisco-based investment firm that focuses on the health care sector, on the Board of Directors.
Following this new appointment, the board will be comprised of seven directors, four of whom including the Chairman are Independent (Iain Ross, Peter Presland, Dr. Bernard Kirschbaum, and Sarah Gordon Wild), two shareholder representative non-executive Directors (Natalie Berner and Dr. Thomas Burt) and Lisa Anson as Chief Executive.
She is a Managing Director focusing on Therapeutics at Redmile, which she joined in 2016. Before Redmile, Natalie was a Research Associate at the New York University School of Medicine. Natalie received a BA in Community Health from Brown University and a Certificate in Premedical Sciences from Columbia University.
About Redx Pharma Plc
Redx Pharma is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic disease, aiming to progress them to clinical proof of concept. Redx’s lead oncology asset, RXC004, is currently in a phase 1 study in patients with advanced malignancies with top-line data expected in mid-2021, and the Company’s selective ROCK2 inhibitor, RXC007, is expected to enter a phase 1 clinical study in H1 2021.
The Company’s core capability of converting medicinal chemistry insights into differentiated and commercially attractive small molecule drug candidates against clinically-validated targets has been recognized by others. Over the last three years, the company has completed four major preclinical stage deals with AstraZeneca, Jazz Pharmaceuticals, and Loxo Oncology (now Eli Lilly).
For more information: https://www.redxpharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
